Imaging Techniques in Alzheimer’s Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring
Open accessThe DOI matches its Crossref record; 228 of the 232 references it cites were found in a registry or an index.
Abstract
Background. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting many individuals worldwide with no effective treatment to date. AD is characterized by the formation of senile plaques and neurofibrillary tangles, followed by neurodegeneration, which leads to cognitive decline and eventually death. Introduction. In AD, pathological changes occur many years before disease onset. Since disease-modifying therapies may be the most beneficial in the early stages of AD, biomarkers for the early diagnosis and longitudinal monitoring of disease progression are essential. Multiple imaging techniques with associated biomarkers are used to identify and monitor AD. Aim. In this review, we discuss the contemporary early diagnosis and longitudinal monitoring of AD with imaging techniques regarding their diagnostic utility, benefits and limitations. Additionally, novel techniques, applications and biomarkers for AD research are assessed. Findings. Reduced hippocampal volume is a biomarker for neurodegeneration, but atrophy is not an AD-specific measure. Hypometabolism in temporoparietal regions is seen as a biomarker for AD. However, glucose uptake reflects astrocyte function rather than neuronal function. Amyloid-β (Aβ) is the earliest hallmark of AD and can be measured with positron emission tomography (PET), but Aβ accumulation stagnates as disease progresses. Therefore, Aβ may not be a suitable biomarker for monitoring disease progression. The measurement of tau accumulation with PET radiotracers exhibited promising results in both early diagnosis and longitudinal monitoring, but large-scale validation of these radiotracers is required. The implementation of new processing techniques, applications of other imaging techniques and novel biomarkers can contribute to understanding AD and finding a cure. Conclusions. Several biomarkers are proposed for the early diagnosis and longitudinal monitoring of AD with imaging techniques, but all these biomarkers have their limitations regarding specificity, reliability and sensitivity. Future perspectives. Future research should focus on expanding the employment of imaging techniques and identifying novel biomarkers that reflect AD pathology in the earliest stages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 The Alzheimer’s disease continuum with corresponding pathological changes, biomarkers and clinical diagnosis. Figure adapted from Yoshiyama et al. [21].](https://figures.cochat.ai/paper-figures/5ed93dc48917473ca30ad0e7a8a74987/imaging-techniques-in-alzheimers-disease-a-review-of-applications-in-early-figure-1.jpg)
![Figure 6 Tau spreading pattern in each Braak stage. Spreading pattern of tau throughout the brain from Braak stage I-II to stage III-IV (limbic regions) and stage V-VI (isocortical areas). Figure adapted from Goedert [145] and created with www.BioRender.com (accessed on 11 February 2021).](https://figures.cochat.ai/paper-figures/f800c1b6e6e24d13ba3b3f4e8509a14d/imaging-techniques-in-alzheimers-disease-a-review-of-applications-in-early-figure-6.jpg)


![Figure 4 Accumulation of amyloid-β in AD. Figure adapted from Patterson et al. [89] and created with www.BioRender.com (accessed on 16 November 2020).](https://figures.cochat.ai/paper-figures/49d3fbddca5e428ea039b5bd152e68a0/imaging-techniques-in-alzheimers-disease-a-review-of-applications-in-early-figure-4.jpg)


![Figure 8 Spreading pattern of amyloid-β accumulation throughout the brain. Amyloid-β accumulation starts in frontal areas and spreads to other regions as disease progresses, leading to a plateau in amyloid-β as disease progresses. Figure adapted from Goedert [145] and created with www.BioRender.com (accessed on 11 February 2021).](https://figures.cochat.ai/paper-figures/d4b1f0c188954fbdb7a6946c934ad246/imaging-techniques-in-alzheimers-disease-a-review-of-applications-in-early-figure-8.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, sMRI and (18FDG)-PET indicate neurodegeneration or neuronal injury in the AT(N) framework with limitations in specifically diagnosing AD.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [370]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They cannot accurately differentiate AD from other neurodegenerative diseases with similar pathologies, such as frontotemporal degeneration and TDP-43 proteinopathies with medial temporal lobe atrophy.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [370]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD diagnosis relies on detecting amyloid and tau pathology via positron emission tomography (PET), magnetic resonance imaging (MRI), and cerebrospinal fluid (CSF) analysis [8,9,10].”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–228 of 228
Pittsburgh Compound‐B (PiB) binds amyloid β‐protein protofibrils
Yamin, G., & Teplow, D. B. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.13887 · Cited by 44 · cited 1×
“Another study reports the strongest PiB binding to Aβ42 fibrils, followed by significant binding to Aβ42 oligomers and protofibrils [100], but compared to the fibril binding, this binding to protofibrils and oligomers is increasingly lower.”
BackgroundWhite Matter Hyperintensities and Cognitive Dysfunction in Alzheimer Disease
Heo, J.-H., Lee, S.-T., Chu, K., Park, H.-J., Shim, J.-Y., & Kim, M. (2009) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988709335800 · Cited by 43
Mini-Mental State Examination Is Sensitive to Brain Atrophy in Alzheimer’s Disease
Fjell, A. M., Amlien, I. K., Westlye, L. T., & Walhovd, K. B. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000241878 · Cited by 43
for the EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders, Drzezga, A. E., Altomare, D., Festari, C., Arbizu, J., Orini, S., Herholz, K., Nestor, P. J., Agosta, F., Bouwman, F. H., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4032-1 · Cited by 43 · cited 1×
“Moreover, hypometabolism is a result of neurodegeneration and, therefore, it might not be suitable to detect signs of AD in the earliest stages before neuronal loss occurs [79].”
BackgroundIs the Alzheimer’s disease cortical thickness signature a biological marker for memory?
Busovaca, E., Zimmerman, M. E., Meier, I. B., Griffith, E. Y., Grieve, S. M., Korgaonkar, M. S., Williams, L. M., & Brickman, A. M. (2015) · Brain Imaging and Behavior · doi:10.1007/s11682-015-9413-5 · Cited by 41 · cited 2×
“Additionally, cortical thickness correlates strongly with cognitive impairment in the clinical stages of AD [41,42].”
BackgroundTau-imaging in neurodegeneration
Bischof, G. N., Endepols, H., van Eimeren, T., & Drzezga, A. E. (2017) · Methods · doi:10.1016/j.ymeth.2017.08.003 · Cited by 41 · cited 2×
“an interesting target for longitudinal monitoring of AD [185].”
BackgroundVanhoutte, M., Semah, F., Sillaire, A. R., Jaillard, A., Petyt, G., Kuchcinski, G., Maureille, A., Delbeuck, X., Fahmi, R., Pasquier, F., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.08.009 · Cited by 41
Friese, U., Meindl, T., Herpertz, S. C., Reiser, M. F., Hampel, H. J., & Teipel, S. J. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1386 · Cited by 36
Waser, M., Benke, T., Dal‐Bianco, P., Garn, H., Mosbacher, J. A., Ransmayr, G. N., Schmidt, R., Seiler, S., Sørensen, H. B. D., & Jennum, P. (2018) · Brain and Behavior · doi:10.1002/brb3.1197 · Cited by 36
Diffusion tensor imaging in Alzheimer’s disease and affective disorders
Teipel, S. J., Walter, M., Likitjaroen, Y., Schönknecht, P., & Gruber, O. (2014) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0496-6 · Cited by 32 · cited 2×
“This technique measures the displacement of water molecules in three dimensions to determine the integrity of the biological tissue [202,203].”
BackgroundMethodBilateral volume reduction in posterior hippocampus in psychosis of epilepsy
Allebone, J., Kanaan, R., Maller, J. J., O'Brien, T., Mullen, S. A., Cook, M. J., Adams, S. J., Vogrin, S. J., Vaughan, D. N., Connelly, A., et al. (2019) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-319396 · Cited by 31 · cited 2×
“In addition to AD, other neurodegenerative diseases are characterized with diminished hippocampal volume as well such as Parkinson’s disease [46], epilepsy [47] and Huntington’s disease [48].”
BackgroundJiang, J., Sun, Y., Zhou, H., Li, S., Huang, Z., Wu, P., Shi, K., Zuo, C., & Initiative, A. D. N. (2018) · Contrast Media & Molecular Imaging · doi:10.1155/2018/3786083 · Cited by 29
Hurtz, S., Chow, N., Watson, A., Somme, J. H., Goukasian, N., Hwang, K., Morra, J., Elashoff, D. A., Gao, S., Petersen, R. C., et al. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.10.012 · Cited by 28
Matveev, S. V., Spielmann, H. P., Metts, B. M., Chen, J., Onono, F., Zhu, H., Scheff, S. W., Walker, L. C., & LeVine, H. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12815 · Cited by 24 · cited 1×
“On a molecular level, PiB is believed to bind insoluble Aβ fibrils [99].”
BackgroundFuture horizons in Alzheimer's disease research
Wısnıewskı, T., & Drummond, E. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.08.001 · Cited by 22 · cited 1×
“Currently, AD is the only cause of death in the top ten deaths globally for which no effective therapeutic treatment is available, and there are no registered drugs to slow down disease progression [10].”
BackgroundMeyer, P., McSweeney, M., Gonneaud, J., & Villeneuve, S. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.05.001 · Cited by 22
Gaonkar, B., Pohl, K. M., & Davatzikos, C. A. (2011) · Lecture notes in computer science · doi:10.1007/978-3-642-23629-7_56 · Cited by 18 · cited 7×
“Pattern-Based Morphometry Another type of morphometry is pattern-based morphometry (PBM), a method with its origin in VBM and DBM [199].”
MethodInfluentialLuzi, F., Savickas, V., Taddei, C., Hader, S., Singh, N., Gee, A. D., & Bongarzone, S. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0329 · Cited by 18 · cited 1×
“11C-FPS-ZM1 is a radiotracer for PET imaging of RAGE in the brain [223].”
BackgroundSohn, B. K., Yi, D., Seo, E. H., Choe, Y. M., Kim, J. W., Kim, S. G., Choi, H. J., Byun, M. S., Jhoo, J. H., Woo, J. I., et al. (2015) · Journal of Korean Medical Science · doi:10.3346/jkms.2015.30.6.779 · Cited by 17
Longitudinal Amyloid-β PET in Atypical Alzheimer’s Disease and Frontotemporal Lobar Degeneration
Whitwell, J. L., Tosakulwong, N., Weigand, S. D., Graff‐Radford, J., Duffy, J. R., Clark, H. M., Machulda, M. M., Botha, H., Utianski, R. L., Schwarz, C. G., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190699 · Cited by 17 · cited 2×
“Furthermore, most studies have used radiolabeled tracers in the typical form of the AD spectrum, resulting in much knowledge about Aβ accumulation in typical AD, while the atypical, non-amnestic type has remained understudied [115].”
BackgroundResultBeta-amyloid imaging in dementia
Chun, K. A. (2018) · Journal of Yeungnam Medical Science · doi:10.12701/yujm.2018.35.1.1 · Cited by 16 · cited 1×
“Many methods have been tested, ranging fr m cognitive tests, MRI scans and sampling of cerebral fluid [22].”
MethodInitiative, A. D. N., Macdonald, K. E., Leung, K. K., Bartlett, J. W., Blair, M., Malone, I. B., Barnes, J., Sebastien Ourselin, A., & Fox, N. C. (2014) · Neuroinformatics · doi:10.1007/s12021-013-9217-y · Cited by 14
A future for PET imaging in Alzheimer’s disease
Kas, A., Migliaccio, R., & Tavitian, B. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04640-w · Cited by 14 · cited 2×
“It is, therefore, necessary to intensively study the dynamic patterns of AD biomarkers in atypical forms of AD in order to understand disease progression in these forms [169].”
BackgroundIshibashi, K., Onishi, A., Wagatsuma, K., Fujiwara, Y., & Ishii, K. (2020) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002948 · Cited by 14 · cited 1×
“These controls were compared with two female subjects that were diagnosed with AD during the study and with a group of fifteen patients in the early stage of AD [166].”
ResultVanhoutte, M., Semah, F., Leclerc, X., Sillaire, A. R., Jaillard, A., Kuchcinski, G., Delbeuck, X., Fahmi, R., Pasquier, F., & Lopes, R. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04519-w · Cited by 9 · cited 1×
“In a more recent study, patients already converted to AD were followed for three years to observe longitudinal changes in cortical glucose metabolism in amnestic and non-amnestic subjects with sporadic AD [165].”
BackgroundShokouhi, S., Campbell, D. L., Brill, A. B., Gwirtsman, H. E., & Initiative, T. A. D. N. (2016) · Brain Pathology · doi:10.1111/bpa.12399 · Cited by 7 · cited 2×
“Since approximately 30% of elderly people suffer from a silent infarct, lacking any clinical manifestations [172], alterations in cerebral glucose metabolism are not surprising in this aged population [173].”
BackgroundVanhoutte, M., Lopes, R., Maureille, A., Delmaire, C., Hossein-Foucher, C., Rollin, A., Semah, F., & Pasquier, F. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.1041 · Cited by 5
(1999) · doi:10.1002/1531-8249(199912)46:6<860::aid-ana8>3.0.co;2-m · cited 1×
“Furthermore, increasing evidence suggests a role for oligomeric Aβ and tau species in the early stages of AD rather than Aβ plaques and NFTs [118,119].”
Background
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Pathogenesis of Alzheimer’s Disease
Rostagno, A. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010107 · Cited by 383
“The manuscript discussed the value of using radiotracers to assess hippocampal volume, hypometabolism in temporoparietal brain regions, and Aβ and Tau accumulation, emphasizing their limitations regarding specificity, reliability, and sensitivity [18].”
BackgroundThe Expanding Burden of Neurodegenerative Diseases: An Unmet Medical and Social Need
Wang, S., Jiang, Y., Yang, A., Meng, F., & Zhang, J. (2024) · Aging and Disease · doi:10.14336/ad.2024.1071 · Cited by 264
Kale, M., Wankhede, N., Pawar, R., Ballal, S., Kumawat, R., Goswami, M., Khalid, M., Taksande, B., Upaganlawar, A., Umekar, M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102497 · Cited by 183
Alzheimer’s Disease Detection Using Deep Learning on Neuroimaging: A Systematic Review
Alsubaie, M. G., Luo, S., & Shaukat, K. (2024) · Machine Learning and Knowledge Extraction · doi:10.3390/make6010024 · Cited by 183
Metadata
- Authors
- van Oostveen, W. M., & de Lange, E. C. M.
- Affiliations
- Faculty of Science, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands
- Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre of Drug Research, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-02-20
- Volume
- 22
- Issue
- 4
- Pages
- 2110
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7924338
- OpenAlex
- W3131910442
- Cited by
- 297
- References
- 232
- Citations by year
- 2026: 47 · 2025: 84 · 2024: 75 · 2023: 55 · 2022: 24 · 2021: 11
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
- Leiden Repository (Leiden University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, neuroimaging biomarkers, early diagnosis, longitudinal disease monitoring, amyloid PET, hippocampal atrophy, hypometabolism, glucose uptake, neurodegeneration, disease-modifying therapy
- MeSH terms
- Alzheimer Disease, Amyloid, Humans, Longitudinal Studies, Biomarkers, Early Diagnosis, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.